Next Generation Sequencing (NGS)
Next Generation Sequencing (NGS)
Next Generation Sequencing
Next-generation sequencing (NGS) is a sequencing technology that offers speed, scalability and ultra-high throughput. The technology can be used to determine the order of nucleotides in entire genomes or targeted regions of DNA or RNA. NGS has applications in environmental, agricultural and forensic science as well as genomic and clinical research.
NGS Capabilities
Whole Exome Sequencing (WES) is a wildly used NGS method that involves sequencing every protein coding region (approximately 21,000 genes) to identify any variants that may increase the risk of developing certain conditions or impact health/lifestyle. WES can be used across a broad range of applications including genetic disease, population genetics and cancer studies.
Advantages
- Attains widespread coverage of coding regions
- Cost effective alternative to Whole-Genome Sequencing (WGS)
- Smaller data set provides faster and easy data analysis compared to WGS approaches
Human Whole Genome Sequencing (hWGS) involves sequencing very single base in your DNA (approximately 3.2 billion) to identify any variants that may increase the risk of developing certain conditions or impact health/lifestyle. This sequencing method has many applications including identifying genetic disorders, mutations responsible for cancer progression, as well as monitoring disease outbreaks.
Advantages
- High-resolution view of the genome
- Detection of all variant types
- Low cost, fast library preparation
16s rRNA gene sequencing involves the analysis of the prokaryotic 16s ribosomal RNA gene which is found in all bacteria and archaea. This sequencing approach is extremely useful for microbiome research studies. 16s rRNA gene sequencing has a number of applications including, environmental, clinical and food
Advantages
- Identification and taxonomic classification of bacterial species
- Fast speed and cost efficient
- Discovery of novel pathogens
Shotgun sequencing reads all the genomic DNA in the sample, rather than just one specific region. This sequencing method provides a vast amount of genetic information as it can identify archaea, bacteria, fungi and viruses.
Advantages
- Less labour intensive than other sequencing methods.
- Faster process than clone-clone sequencing
- Requires less DNA
qPCR
qPCR allows for the analysis of particular variants of specific locations. It is a good choice when interrogating a small region of DNA on a limited number of samples. Real-time PCR can be used for both qualitative and quantitative analysis.
Advantages and Applications of qPCR
Next Generation Sequencing (NGS) Advantages
High sample throughput
High sensitivity
Comprehensive genomic coverage
Can sequence thousands of genes simultaneously
- Low sample input required
Fast turnaround time for high sample volumes
Related Services
CDx & Biopharma Services
Genotyping Services
Genotyping Services
The Randox Genomics Services Department currently has target genotyping solutions in multiple areas. Genotyping is the process of analysing DNA to detect SNPs of interest. These SNPs are compared to reference SNPs, available from years of genetic research, to determine differences in genetic makeup.
Genotyping Advantages and Applications
Clinical Diagnostics
Clinical Research
Food & Agriculture
Pharmacogenomics
Pharmacogenomics (PGx) is the study of how a person’s DNA effects their drug response. This is a relatively new field in science but it is expected to be the future of medicine as it focuses on personalised medicine and treating every patient individually.
Microarray Technology for PGx
At Randox we use Illumina’s Infinium Global Diversity Array with Enhanced PGx microarray to test for pharmacogenomic markers. This is the most comprehensive genotyping microarray on the market for pharmacogenomic research. The microarray features over 44,000 genome-wide PGx markers which span more than 20000 pharmacogenomic targets and gives 100% coverage of priority level A and B CPIC genes.
Related Services
CDx & Biopharma Services
Genomics Services
Genomics Services
An End-to-End Genomics Solution
Randox Genomics Services department is fitted with specialised, fully equipped, state of the art testing facilities, designed and set up to fulfil a unique range of end-to-end sequencing solutions inclusive of in-house bioinformaticians and data analysts.
Why Randox?
Randox Laboratories is a global market leader within the in vitro diagnostics industry. Utilising a multitude of platforms, our sequencing and genotyping facility is suited to a wide range of areas of genome sequencing.
Our team of genetic scientists and bioinformaticians provide customisable sequencing and genotyping services for research, development, validation and running of different genomic tests to generate high quality data in line with modern healthcare and future disease insights.
A dedicated team of genetic scientists including automation specialists, enabling adaption to testing throughputs changes from call small projects to large scale testing.
Huge capacity for storage and accessioning of multiple sample types with fast turnaround times.
Specific customised project planning and validation of services, tailored to the needs of each Randox customer.
Multiple options for variable throughput from low throughput instruments, to the largest sequencer on the market with targeted solutions in multiple areas.
- Targeted genotyping solutions in multiple areas
Our Services
Related Services
CDx & Biopharma Services
OLINK
OLINK® | Comprehensive Biomarker Discovery
Let Experts at Randox Run Your Samples
As one of the UK’s first commercial partners of Olink® Proximity Extension Assay (PEA) technology, a sensitive and high-throughput technology. In PEA, pairs of oligonucleotide-labeled antibodies are used to capture and detect target proteins, and the proximity of the antibodies leads to the formation of a DNA amplicon that can be quantified by qPCR or Next Generation Sequencing (NGS).
Randox offer scientists involved in drug development, clinical, or basic life science research, the service they need to run large-scale discovery proteomics.
Considered as a next-gen proteomics platform, Olink® technology is widely recognised and extensively cited in various research fields for protein profiling and biomarker development.
As an Olink® Certified Service Provider, Randox are experts in generating high-quality data using all Olink® proteomic platforms.
Supported Olink® Platforms
Proteomics are critical for understanding disease pathology and accelerating protein biomarker discovery.
Randox Service portfolio includes high throughput protein analysis using cutting-edge Olink® technology, a significant leap forward in next generation, disruptive proteomics with proven specificity. We are experts in generating high-quality data using all Olink® proteomic platforms.
Allow the Randox team to assist you in discovering how this versatile assay can advance your research by getting in touch.
Olink® Explore HT
Proteins (per panel): 5,400 + with proven specificity of 99.5% negligible cross-reactivity
Sample: 2 µL
Multiplex Panels: 1
Quantification: Relative with NGS automated workflow readout
Olink® Explore 384
Proteins (per panel) ~3000 high-multiplex biomarker discover with uncompromised data quality
Sample: 1 µL
Multiplex Panels: 8
Quantification: Relative
Olink® Target 96
Proteins (per panel) ~ 1100 covering 15 panels for biological processes and disease areas
Sample: 1 µL
Multiplex Panels: 15 with 92 proteins per panel
Quantification: Relative
Olink® Target 48 Cytokine
Proteins (panels): Each panel contains up to 45 immune-related proteins. These two panels can be combined and processed simultaneously.
Sample: 1 µL
Multiplex Panels: 1
Quantification: Relative
Olink® Flex
Proteins (per panel) ~200 within the complete protein library. Each panel contains between 15-21 proteins.
Sample: 1 µL
Multiplex Panels: Mix & Match with combinability of 99% compared to industry-leading standards.
Quantification: Relative or absolute
Olink® Focus
Proteins (per panel) 5400+ with proven specificity. Custom panels with up to 21 proteins for actionable clinical breakthroughs, designed to empower biomarker utility.
Sample: 1 µL
Multiplex Panels: Custom
Quantification: Relative or absolute
Features and Benefits
- Covers all major biological pathways with ~5400 + validated protein assays
- High sample throughput for large scale proteomic studies and research
- Minimal sample volume with just 60uL for the complete library
- Exceptional specificity in comparison to mass spec utilising PEA technology
- Compatible with a wide variety of sample types
Olink® Workflow
Randox Successfully Completed Olink® Concordance Testing
Randox successfully completed the Explore Concordance challenge as beta testers of the Concordance program, certifying the ability to operate the PEA with the same level of competency as the Olink® Analysis Service.
| Randox Summary Report | Acceptance Criteria | Result | |
|---|---|---|---|
| QC Warnings | 0% | Max 16% allowed | Passed the QC warning criteria |
| Detectability | 97.2% | Min 85% allowed | Passed the detectability criteria |
| Intra CV | 9% | Max 15% allowed | Passed the CV criteria |
| Median correlation coefficient (r) | 0.98 | Min 0.9 allowed | Passed the correlation criteria. |
| Coefficient of determination (R2) | 0.96 | Min 0.9 allowed | Passed the correlation criteria. |
Overall, Randox passed all QC criteria, successfully passing the Olink Concordance Test on Explore 3072.
Related Services
CDx & Biopharma Services
Vivalytic | Monkeypox (MPXV)
Vivalytic | MPXV
–
Detection of Monkeypox Virus and non-variola Orthopoxvirus species.
*Research Use Only
RT-PCR detection of Monkeypox Virus and non-variola Orthopoxvirus species.
- Quick turnaround time of 45 minutes, beneficial for both the patient and for the containment of Monkeypox
- Convenient 4 step process from sample entry to results. Suitable for use in laboratory and non-laboratory settings
- Two target approach: Detection of MPXV and Orthopoxvirus species (including MPXV)
Clinical Significance
Vivalytic Monkeypox virus (MPXV) is a rapid and user-friendly test designed to aid the global response against Monkeypox. Monkeypox is a zoonotic virus belonging to the Orthopoxvirus subset genus within the Poxviridae family. It spreads between species through animal bites and the transfer of bodily fluids. Human-to-human transmission can occur through contact with infected lesions, inhalation of respiratory droplets, and indirect exposure to contaminated objects. Sexual contact is recognised as a significant mode of transmission during outbreaks of infection.
The Vivalytic MPXV Panel is specifically developed to detect the presence of the Monkeypox virus and non-variola orthopoxvirus species. With a remarkable time-to-result of just 45 minutes, this cutting-edge test offers swift and accurate screening of these viral pathogens, improving outbreak containment and prevention.
Features
Sample Type: Swab
Sample Volume: 300μL
Detection Method: Real-Time PCR
Time to result: 45 minutes
| Detectable Pathogens | |
|---|---|
| Monkeypox Virus (Clade I, Clade II) | Non-variola Orthopoxvirus species (Coqpox Virus, Ectromelia Virus, Monkeypox Virus, Taterapox Virus, Vaccinia Virus) |
“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”
Vivalytic Workflow
Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.
To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.
The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.
Want to know more?
Contact us or visit our COVID-19 Monitoring & Management page
Related Products
Viral Respiratory Infection Array
SARS-CoV-2 Pooling Test
Vivalytic
Vivalytic Test Menu
Randox Biosciences Resource Hub
Biosciences Overview
Your Next Trusted Partner
What we do.
As an established IVD company, Randox Biosciences offers tailored development and testing solutions to support faster, more effective and safe development of new therapeutics. We aim to advance scientific discovery, drug development & diagnostics.
From initial cultivation of raw materials for assay development, through to providing companion diagnostics, molecular and protein based custom assays across a range of therapeutic areas, we assist Pharma, Biotechs and CROs move away from a “one treatment fits all” approach. Our aim is to advance the future of personalised medicine approaches to enable a better understanding of the complexity and variability of disease and increase efficacy of treatment.
Randox Biosciences are your next trusted partner to achieve precise results, for faster drug approval through successful assay design, validation, registrations and co-commercialisation globally.
Randox Biosciences are a world leading manufacturer of Bioreagents including, high -quality monoclonal and polyclonal antibody fragments and human recombinant proteins to assist diagnostic manufacturers. We also strive to assist clinical trials globally to reach their potential with the ability to provide multiplex technology, custom assay development, along with outsourcing solutions for testing.
Additionally, Randox Biosciences provides a wide range of assay formats including single nucleotide polymorphisms (SNP) genotyping, pathogen detection and mutation detection. Offering complete flexibility to achieve success in any collaborative partnership, assay development can be optimised for use on a wide range of third-party instruments and with the Randox Evidence Series – Biochip Technology platforms.
Our Expertise.
CDx & BioPharma Services
RCLS Testing
BioReagents
Biosciences Resource Hub